Skip to main content
Smart Investors Daily
CE

NASDAQ · CERT

Certara, Inc.

Healthcare · Medical - Healthcare Information Services

$11.18

Down-$0.50 (-4.47%)

Updated Nov 20, 2026, 1:06 AM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.42B
P/E ratio
177.53
Dividend yield
0.00%
52-week range
$4.45 – $12.61
Volume
1.75M
Avg. volume
2.12M

Price performance · CERT

CERT price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 18, 2026

CERT closed at $11.18 after 20 trading sessions, up 10.80% for the selected period.

Last close
$11.18
Period change
+10.80%
Period low
$10.09
Period high
$12.22
Daily close
View OHLC price history
CERT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 18, 2026$11.02$11.355$11.00$11.181.75M
Nov 17, 2026$11.29$11.54$11.05$11.062.28M
Nov 16, 2026$11.35$11.46$11.15$11.392.84M
Nov 13, 2026$12.02$12.1777$11.545$11.572.67M
Nov 12, 2026$11.73$11.97$11.29$11.903.12M
Nov 11, 2026$12.25$12.38$11.67$11.733.16M
Nov 10, 2026$12.00$12.27$11.85$12.1252.88M
Nov 9, 2026$12.06$12.60$11.98$12.225.84M
Nov 6, 2026$12.03$12.61$11.79$12.054.87M
Nov 5, 2026$11.21$12.25$10.82$12.183.73M
Nov 4, 2026$11.08$11.275$10.7801$11.092.43M
Nov 3, 2026$10.58$11.02$10.4598$10.871.87M
Nov 2, 2026$11.08$11.09$10.645$10.711.95M
Oct 30, 2026$11.07$11.19$10.645$11.021.95M
Oct 29, 2026$11.46$11.57$11.08$11.202.75M
Oct 28, 2026$10.84$11.73$10.84$11.482.37M
Oct 27, 2026$10.50$10.98$10.435$10.952.42M
Oct 26, 2026$10.20$10.625$10.0793$10.612.35M
Oct 23, 2026$9.95$10.37$9.835$10.332.06M
Oct 22, 2026$10.14$10.31$9.86$10.092.37M

Latest CERT news

The latest Smart Investors Daily articles mentioning CERT.

CERT research

Overview

Company profile and research snapshot.

Company profile

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$13.00
Implied upside
—
Analysts
—
CERT recent ratings
DateFirmRatingTarget
Nov 6, 2026BarclaysEqual-Weight—
Oct 16, 2026KeybancOverweight—
Oct 13, 2026TD CowenBuy—
Oct 7, 2026BarclaysEqual-Weight—
Sep 30, 2026UBSNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 6, 2026

Why Did Certara (CERT) Shares Climb After Its Latest Update?

How Certara’s Q3 earnings changed the conversation Certara (CERT) put fresh numbers on the table with its Q3 2026 report, giving investors new data on profitability, software momentum, and the trade off between quarterly strength and year to date losses. Sales for the quarter reached US$94.9 million compared with US$90.89 million a year earlier, while net income was US$5.59 million compared with US$1.53 million. Earnings per share for the period came in at US$0.04 on both a basic and diluted...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.